Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center
<b>Introduction:</b> The BNT162b2 vaccination studies did not specifically focus on groups that were heavily exposed to SARS-CoV-2 infection. Therefore, we aimed to assess the safety and efficacy of the BNT162b2 vaccine among healthcare workers (HCWs). <b>Methods:</b> Study p...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/12/2158 |
| _version_ | 1797455027498909696 |
|---|---|
| author | Agata Skrzat-Klapaczyńska Justyna Dominika Kowalska Marcin Paciorek Joanna Puła Carlo Bieńkowski Dominika Krogulec Jarosław Stengiel Agnieszka Pawełczyk Karol Perlejewski Sylwia Osuch Marek Radkowski Andrzej Horban |
| author_facet | Agata Skrzat-Klapaczyńska Justyna Dominika Kowalska Marcin Paciorek Joanna Puła Carlo Bieńkowski Dominika Krogulec Jarosław Stengiel Agnieszka Pawełczyk Karol Perlejewski Sylwia Osuch Marek Radkowski Andrzej Horban |
| author_sort | Agata Skrzat-Klapaczyńska |
| collection | DOAJ |
| description | <b>Introduction:</b> The BNT162b2 vaccination studies did not specifically focus on groups that were heavily exposed to SARS-CoV-2 infection. Therefore, we aimed to assess the safety and efficacy of the BNT162b2 vaccine among healthcare workers (HCWs). <b>Methods:</b> Study participants were recruited from hospital employees who received BNT162b2 vaccination at the Hospital for Infectious Diseases in Warsaw. Blood samples were collected before and after each vaccination dose. At each timepoint, the levels of anti-SARS CoV-2 IgM, anti-n SARS-CoV-2 IgG, and S-RBD antibodies were measured. Data on concomitant diseases and the vaccine’s adverse events (VAE) were collected after each vaccination dose. In the statistical analyses, non-parametric tests were used. <b>Results:</b> In total, 170 healthcare workers were included in the analysis. Their median age was 51 years (interquartile range (IQR): 41–60 years); most of them were women (<i>n</i> = 137, 80.6%) working in direct contact with patients (<i>n</i> = 137, 73.2%); and 46 (27.0%) had concomitant diseases. More than one fifth of subjects had COVID-19 before their first dose of vaccination (<i>n</i> = 38, 22.6%). In terms of immunological responses, our investigations showed a high level of efficacy for the BNT162b2 mRNA vaccination as measured by S-RBD antibody concentrations: these were positive in 100% of participants 14 days after the second dose of the vaccine. It was also observed that employees with high S-RBD antibodies (>=433 BAU/mL) were more likely to be COVID-19 convalescents before receiving the first vaccine dose (<i>p</i> < 0.001). <b>Conclusion:</b> The BNT162b2 vaccine is safe and effective among HCWs. Vaccine adverse events occurred, but serious events were not observed. Moreover, the BNT162b2 vaccine is effective against symptomatic and severe COVID-19—none of the workers that acquired a SARS-CoV-2 infection after vaccination required hospitalization or medical care. We also observed higher immunological responses among COVID-19 convalescents. |
| first_indexed | 2024-03-09T15:45:39Z |
| format | Article |
| id | doaj.art-465d19d91a8847c6ab8e2a63707e879b |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T15:45:39Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-465d19d91a8847c6ab8e2a63707e879b2023-11-24T18:33:46ZengMDPI AGVaccines2076-393X2022-12-011012215810.3390/vaccines10122158Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases CenterAgata Skrzat-Klapaczyńska0Justyna Dominika Kowalska1Marcin Paciorek2Joanna Puła3Carlo Bieńkowski4Dominika Krogulec5Jarosław Stengiel6Agnieszka Pawełczyk7Karol Perlejewski8Sylwia Osuch9Marek Radkowski10Andrzej Horban11Department of Adults’ Infectious Diseases, Medical University of Warsaw, 02-091 Warsaw, PolandDepartment of Adults’ Infectious Diseases, Medical University of Warsaw, 02-091 Warsaw, PolandDepartment of Adults’ Infectious Diseases, Medical University of Warsaw, 02-091 Warsaw, PolandDepartment of Adults’ Infectious Diseases, Medical University of Warsaw, 02-091 Warsaw, PolandDepartment of Adults’ Infectious Diseases, Medical University of Warsaw, 02-091 Warsaw, PolandDepartment of Adults’ Infectious Diseases, Medical University of Warsaw, 02-091 Warsaw, PolandWard 7th, Hospital for Infectious Diseases, 01-201 Warsaw, PolandDepartment of Immunopathology of Infectious and Parasitic Diseases, Medical University in Warsaw, 02-091 Warsaw, PolandDepartment of Immunopathology of Infectious and Parasitic Diseases, Medical University in Warsaw, 02-091 Warsaw, PolandDepartment of Immunopathology of Infectious and Parasitic Diseases, Medical University in Warsaw, 02-091 Warsaw, PolandDepartment of Immunopathology of Infectious and Parasitic Diseases, Medical University in Warsaw, 02-091 Warsaw, PolandDepartment of Adults’ Infectious Diseases, Medical University of Warsaw, 02-091 Warsaw, Poland<b>Introduction:</b> The BNT162b2 vaccination studies did not specifically focus on groups that were heavily exposed to SARS-CoV-2 infection. Therefore, we aimed to assess the safety and efficacy of the BNT162b2 vaccine among healthcare workers (HCWs). <b>Methods:</b> Study participants were recruited from hospital employees who received BNT162b2 vaccination at the Hospital for Infectious Diseases in Warsaw. Blood samples were collected before and after each vaccination dose. At each timepoint, the levels of anti-SARS CoV-2 IgM, anti-n SARS-CoV-2 IgG, and S-RBD antibodies were measured. Data on concomitant diseases and the vaccine’s adverse events (VAE) were collected after each vaccination dose. In the statistical analyses, non-parametric tests were used. <b>Results:</b> In total, 170 healthcare workers were included in the analysis. Their median age was 51 years (interquartile range (IQR): 41–60 years); most of them were women (<i>n</i> = 137, 80.6%) working in direct contact with patients (<i>n</i> = 137, 73.2%); and 46 (27.0%) had concomitant diseases. More than one fifth of subjects had COVID-19 before their first dose of vaccination (<i>n</i> = 38, 22.6%). In terms of immunological responses, our investigations showed a high level of efficacy for the BNT162b2 mRNA vaccination as measured by S-RBD antibody concentrations: these were positive in 100% of participants 14 days after the second dose of the vaccine. It was also observed that employees with high S-RBD antibodies (>=433 BAU/mL) were more likely to be COVID-19 convalescents before receiving the first vaccine dose (<i>p</i> < 0.001). <b>Conclusion:</b> The BNT162b2 vaccine is safe and effective among HCWs. Vaccine adverse events occurred, but serious events were not observed. Moreover, the BNT162b2 vaccine is effective against symptomatic and severe COVID-19—none of the workers that acquired a SARS-CoV-2 infection after vaccination required hospitalization or medical care. We also observed higher immunological responses among COVID-19 convalescents.https://www.mdpi.com/2076-393X/10/12/2158COVID-19 vaccinationhealthcare workersCOVID-19 convalescentimmunological responseantibodies |
| spellingShingle | Agata Skrzat-Klapaczyńska Justyna Dominika Kowalska Marcin Paciorek Joanna Puła Carlo Bieńkowski Dominika Krogulec Jarosław Stengiel Agnieszka Pawełczyk Karol Perlejewski Sylwia Osuch Marek Radkowski Andrzej Horban Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center Vaccines COVID-19 vaccination healthcare workers COVID-19 convalescent immunological response antibodies |
| title | Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center |
| title_full | Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center |
| title_fullStr | Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center |
| title_full_unstemmed | Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center |
| title_short | Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center |
| title_sort | higher immunological response after bnt162b2 vaccination among covid 19 convalescents the data from the study among healthcare workers in an infectious diseases center |
| topic | COVID-19 vaccination healthcare workers COVID-19 convalescent immunological response antibodies |
| url | https://www.mdpi.com/2076-393X/10/12/2158 |
| work_keys_str_mv | AT agataskrzatklapaczynska higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter AT justynadominikakowalska higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter AT marcinpaciorek higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter AT joannapuła higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter AT carlobienkowski higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter AT dominikakrogulec higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter AT jarosławstengiel higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter AT agnieszkapawełczyk higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter AT karolperlejewski higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter AT sylwiaosuch higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter AT marekradkowski higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter AT andrzejhorban higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter |